文献速递腹部技术与安全CT

双层光谱探测器CT:一种无创同步预测胰腺导管腺癌Ki-67增殖状态与p53突变的工具

Dual-layer spectral detector CT: a non-invasive tool for simultaneously predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2025-07-14

本研究回顾性纳入92例未经治疗、病理确诊的胰腺导管腺癌患者,评估双层光谱探测器CT预测Ki-67增殖状态与p53突变的价值。动脉期归一化碘浓度是两者唯一的独立预测因子,以0.090为截断值时预测Ki-67增殖状态的AUC为0.812、敏感度87.5%、特异度75.0%,预测p53突变的AUC为0.731、敏感度76.7%、特异度69.4%。

要点

  • 动脉期归一化碘浓度(nICa)是Ki-67增殖状态与p53突变的唯一独立预测因子。
  • nICa预测Ki-67高表达(≥25%)的AUC为0.812,敏感度87.5%、特异度75.0%。
  • nICa预测p53突变的AUC为0.731,敏感度76.7%、特异度69.4%。

核心结论

  • DLCT参数nICa可同时、无创地预测PDAC的Ki-67增殖状态与p53突变,诊断效能令人满意。

研究设计与样本

  • 回顾性研究,纳入2019年6月至2023年9月间接受DLCT检查、未经治疗且病理确诊的PDAC患者92例(年龄60.19±11.22岁,男性61例)。

诊断标准与关键数值

  • nICa预测Ki-67增殖状态的截断值为0.0910(p<0.001;调整OR 2.33;95%CI 1.46, 3.74),预测p53突变的截断值为0.0905(p<0.001;调整OR 1.35;95%CI 1.07, 1.71)。

临床应用与阅片要点

  • 采用取整截断值0.090时,nICa预测Ki-67增殖状态的AUC为0.812、敏感度87.5%、特异度75.0%;预测p53突变的AUC为0.731、敏感度76.7%、特异度69.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the value of dual-layer spectral detector CT (DLCT) for predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma (PDAC).

MATERIALS &amp; METHODS: This retrospective study included untreated patients with pathologically confirmed PDAC who underwent DLCT between June 2019 and September 2023. Independent relevant clinical-radiological features and quantitative parameters for predicting Ki-67 proliferation status and p53 mutations were identified using multivariate logistic regression analysis. The diagnostic performances of independent variables were evaluated using receiver operating characteristic curves.

RESULTS: We included 92 patients (60.19 ± 11.22 years old, 61 males). There were 40 patients with high Ki-67 expression (Ki-67 ≥ 25%) and 43 patients positive for p53 mutation. The radiologists showed substantial or near-perfect inter- and intra-observer agreement in evaluating quantitative parameters. Normalised iodine concentration in the arterial phase (nICa) was the only independent predictor of Ki-67 proliferation status (p < 0.001; adjusted odds ratio [OR], 2.33; 95% confidence interval [CI]: 1.46, 3.74; cut-off, 0.0910) and p53 mutations (p < 0.001; adjusted OR, 1.35; 95% CI: 1.07, 1.71; cut-off, 0.0905) according to the multivariate logistic analysis. nICa showed satisfactory performance when using the chosen rounded cut-off value of 0.090 (easily applicable in clinical practice) in predicting Ki-67 proliferation (area under the receiver operating characteristic curve [AUC], 0.812; sensitivity, 87.5%; specificity, 75.0%) and p53 mutations (AUC, 0.731; sensitivity, 76.7%; specificity, 69.4%).

CONCLUSION: The DLCT parameter nICa enables simultaneous and non-invasive prediction of both Ki-67 proliferation status and p53 mutations in PDAC with satisfactory diagnostic efficacy.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Yuan J, Liu J, Chen M, et al. Dual-layer spectral detector CT: a non-invasive tool for simultaneously predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2025. PMID: 40658136. doi:10.1007/s00261-025-05115-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。